GENTA INCORPORATED /DE/
10-Q, EX-27, 2000-08-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: GENTA INCORPORATED /DE/, 10-Q, EX-10.2, 2000-08-14
Next: DECRANE AIRCRAFT HOLDINGS INC, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEETS AND CONSOLIDATED STATEMENTS OF OPERATIONS CONTAINED
IN THE COMPANY'S QUARTERLY REPORT ON FROM 10-Q FOR PERIOD ENDED JUNE 30, 2000
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   6-MOS                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999             DEC-31-2000
<PERIOD-START>                             JAN-01-1999             JAN-01-2000
<PERIOD-END>                               JUN-30-1999             JUN-30-2000
<CASH>                                       3,224,878               6,899,677
<SECURITIES>                                   501,400               1,277,479
<RECEIVABLES>                                1,400,000               1,577,115
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                             5,361,096               9,872,246
<PP&E>                                          36,203                  41,370
<DEPRECIATION>                                       0                       0
<TOTAL-ASSETS>                               6,540,407              13,218,366
<CURRENT-LIABILITIES>                        2,594,140               2,177,508
<BONDS>                                              0                       0
                                0                       0
                                        410                     269
<COMMON>                                        18,222                  43,560
<OTHER-SE>                                   3,927,635              10,997,029
<TOTAL-LIABILITY-AND-EQUITY>                 6,540,407              13,218,266
<SALES>                                              0                       0
<TOTAL-REVENUES>                                     0                       0
<CGS>                                                0                       0
<TOTAL-COSTS>                                4,156,984              12,440,750
<OTHER-EXPENSES>                               149,114                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                              82,931                 258,541
<INCOME-PRETAX>                            (1,939,149)            (11,676,242)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                        (1,939,149)            (11,676,242)
<DISCONTINUED>                               (189,407)                       0
<EXTRAORDINARY>                              1,606,956                       0
<CHANGES>                                            0                       0
<NET-INCOME>                               (3,437,948)            (15,118,803)
<EPS-BASIC>                                     (0.23)                  (0.49)
<EPS-DILUTED>                                   (0.23)                  (0.49)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission